Serina Therapeutics Inc. (SER)
4.42
-0.42 (-8.68%)
At close: Mar 25, 2025, 3:59 PM
4.67
5.66%
After-hours: Mar 25, 2025, 07:01 PM EDT
-8.68% (1D)
| Bid | 4.42 |
| Market Cap | 39.3M |
| Revenue (ttm) | 112.52K |
| Net Income (ttm) | -6.31M |
| EPS (ttm) | 0.16 |
| PE Ratio (ttm) | 27.63 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.5 |
| Volume | 8,642 |
| Avg. Volume (20D) | 13,584 |
| Open | 4.80 |
| Previous Close | 4.84 |
| Day's Range | 4.37 - 4.80 |
| 52-Week Range | 3.81 - 19.93 |
| Beta | 0.86 |
About SER
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for...
Industry Biotechnology
Sector Healthcare
IPO Date Jan 21, 2000
Employees 9
Stock Exchange NYSE
Ticker Symbol SER
Website https://serinatherapeutics.com
Analyst Forecast
According to 1 analyst ratings, the average rating for SER stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 148.87% from the latest price.
Stock Forecasts3 months ago
+19.16%
Serina Therapeutics shares are trading higher. The...
Unlock content with
Pro Subscription
